Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matejka Rebolj

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|December 3, 2014
Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytologyMatejka Rebolj, Elsebeth Lynge, Ditte Ejegod, et al.
International Journal of Cancer|October 18, 2020
Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testingLeonardo I Green, Christopher S Mathews, Jo Waller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2015
A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30yearsMatejka Rebolj, Jesper Bonde, Ditte Ejegod, et al.
Breast Cancer Research and Treatment|July 1, 2021
Variations in pathways and resource use in follow-up after abnormal mammography screening: a nationwide register-based studySusanne Fogh Jørgensen, Berit Andersen, Anders Lernevall, et al.
British Journal of Cancer|March 29, 2022
The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilotMatejka Rebolj, Francesca Pesola, Christopher Mathews, et al.
Journal of Clinical Microbiology|August 19, 2016
Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial AssaysMatejka Rebolj, Jesper Bonde, Sarah Preisler, et al.
International Journal of Cancer|July 22, 2006
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the NetherlandsAnita B Bos, Matejka Rebolj, J Dik F Habbema, et al.
Plos One|January 21, 2016
Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and AboveMatejka Rebolj, Jesper Bonde, Sarah Preisler, et al.
Plos One|January 28, 2014
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screeningMatejka Rebolj, Sarah Preisler, Ditte Møller Ejegod, et al.
Cancer Medicine|November 12, 2021
Adherence to follow-up after the exit cervical cancer screening test at age 60-64: A nationwide register-based studySusanne F Jørgensen, Berit Andersen, Lone Kjeld Petersen, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|December 3, 2014
Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytologyMatejka Rebolj, Elsebeth Lynge, Ditte Ejegod, et al.
International Journal of Cancer|October 18, 2020
Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testingLeonardo I Green, Christopher S Mathews, Jo Waller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2015
A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30yearsMatejka Rebolj, Jesper Bonde, Ditte Ejegod, et al.
Breast Cancer Research and Treatment|July 1, 2021
Variations in pathways and resource use in follow-up after abnormal mammography screening: a nationwide register-based studySusanne Fogh Jørgensen, Berit Andersen, Anders Lernevall, et al.
British Journal of Cancer|March 29, 2022
The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilotMatejka Rebolj, Francesca Pesola, Christopher Mathews, et al.
Journal of Clinical Microbiology|August 19, 2016
Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial AssaysMatejka Rebolj, Jesper Bonde, Sarah Preisler, et al.
International Journal of Cancer|July 22, 2006
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the NetherlandsAnita B Bos, Matejka Rebolj, J Dik F Habbema, et al.
Plos One|January 21, 2016
Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and AboveMatejka Rebolj, Jesper Bonde, Sarah Preisler, et al.
Plos One|January 28, 2014
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screeningMatejka Rebolj, Sarah Preisler, Ditte Møller Ejegod, et al.
Cancer Medicine|November 12, 2021
Adherence to follow-up after the exit cervical cancer screening test at age 60-64: A nationwide register-based studySusanne F Jørgensen, Berit Andersen, Lone Kjeld Petersen, et al.
Pageof 9